---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-197047"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:18:49.481315+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AN2 discontinues EBO-301 MAC lung study, cuts ~50% workforce, shifts pipeline focus

## Summary
- Phase 2/3 EBO-301 study discontinued; sputum culture conversion at Month 6: 13.2% vs 10.0% (p=0.64).
- Reduction in force of ~50% of employees; expects $2-3M in severance charges.
- CMO Paul Eckburg departs Aug 30, 2024; will continue as consultant with vesting.
- Company shifts focus to boron chemistry platform; plans Phase 1 for Chagas, Phase 2 for melioidosis.
- Cost savings expected to extend cash runway through 2027.

## SEC filing metadata
- accession: 0001193125-24-197047
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/0001193125-24-197047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/d865374d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-197047
- JSON: https://secwatch.observer/filing/0001193125-24-197047.json
- Plain text: https://secwatch.observer/filing/0001193125-24-197047.txt

## Key facts
- Executive change
  Paul Eckburg departed as Chief Medical Officer at AN2 Therapeutics, Inc..
  - Action: departed
  - Role: Chief Medical Officer
  source text: Paul Eckburg, M.D., the Company’s Chief Medical Officer, will depart the Company effective as of August 30, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/0001193125-24-197047-index.htm
- Restructurings & Charges
  AN2 Therapeutics, Inc. announced a restructuring with charges of approximately $2-$3 million (approximately 50% of the Company's employee workforce).
  - Type: restructuring
  - Charge: approximately $2-$3 million
  - Headcount: approximately 50% of the Company's employee workforce
  source text: On August 7, 2024, the Board of Directors of AN2 Therapeutics, Inc. (the “Company”) approved a reduction in force that is intended to result in the termination of approximately 50% of the Company’s employee workforce.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/0001193125-24-197047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.